ZGNX - Tevard Biosciences and Zogenix collaborate for advancement on dravet syndrome and other genetic epilepsies

Tevard Biosciences and Zogenix (ZGNX) collaborate to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies.Zogenix is responsible for funding the collaboration, Tevard will receive an initial collaboration payment of $10M, of which ~$5M has previously been paid by Zogenix. Tevard is also eligible to receive additional development, regulatory and commercial-related milestone payments ranging from $70M-100M for each program, as well as tiered royalties on future net global sales on any commercial products that result from the collaboration.More insight in contributor article 'Zogenix Has A Wide Margin Of Safety After A 60% Sell-Off'

For further details see:

Tevard Biosciences and Zogenix collaborate for advancement on dravet syndrome and other genetic epilepsies